Gene therapy in the early stages of retinal degeneration.

Competing Interests: REM is a named inventor on several retinal gene therapy patents owned by the University of Oxford, but none are related to the product discussed in this Comment. REM has been a consultant to the following companies: Beacon Therapeutics, Scribe Therapeutics, AGTC, SpliceBio, and Syncona Partners, working on retinal gene therapy, but none are pursuing treatments relevant to GUCY2D or any other programmes discussed in this Comment. REM is a full-time employee of the University of Oxford, which owns and licenses patents through Oxford University Innovation. REM is a scientific cofounder of Beacon Therapeutics, together with the University of Oxford, but is not a member of the board. REM is an advisor to the UK National Institute for Health and Care Excellence, the US Food and Drug Administration, and the European Medicines Agency on treatments for inherited retinal diseases, but not related to any product discussed in this Comment.